Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne. · herb
Evidence tier: limited
Relieves musculoskeletal pain and lower back pain
Harpagoside, an iridoid glycoside, is the constituent trials standardise on and the one credited with the effect. Laboratory work points to suppression of inflammatory signalling, including cyclooxygenase and inducible nitric oxide synthase expression. This is the plausible explanation, not a demonstrated mechanism in people, and the dose response in humans has never been mapped.
Limited, and the honest verdict is 'a real signal at low certainty, for low back pain, short term'. The Cochrane review 'Herbal medicine for low back pain' (CD004504) is the best source and it is careful: 'Daily doses of H. procumbens standardized to 50 mg or 100 mg harpagoside may be better than placebo for short term improvements in pain and reduced use of rescue medication (two trials, 315 participants, LOW QUALITY EVIDENCE).' A separate trial showed 'relative equivalence to 12.5 mg per day of rofecoxib (one trial, 88 participants, VERY LOW QUALITY EVIDENCE).' Note what Cochrane did NOT do: when the review reached its practice implications, it singled out topical Capsicum frutescens and Symphytum officinale as the preparations that 'appear to reduce pain more than placebo', and gave devil's claw no explicit endorsement. Cochrane also states there is 'no evidence to suggest that any of these substances are safe and useful for long term use'. The osteoarthritis evidence is thinner than the back pain evidence, not stronger. Europe's regulator agrees with the modest read: the EMA HMPC monograph on Harpagophytum procumbens and/or Harpagophytum zeyheri, radix registers it as a TRADITIONAL herbal medicinal product for minor joint pain and for mild digestive complaints, NOT as well established use, meaning the registration rests on long standing use and not on the trial data. So the fair summary is: two low quality trials point the right way at a standardised harpagoside dose, one very low quality trial suggests NSAID like effect, the regulator declined to grant well established use, and nobody has shown it is safe long term.
The trial relevant dose is the one Cochrane standardises on: 50 mg or 100 mg of harpagoside daily. EMA traditional use, adults: dried root as herbal tea 4.5 g per day (in 500 ml boiling water, divided into 3 doses) for minor joint pain, or 1.5 g per day for mild digestive complaints. Extract daily doses vary by preparation (for example water dry extract up to 2.4 g per day). Harpagoside content, not root weight, is what the evidence actually tracks.
With meals. Allow 4 to 6 weeks for full anti inflammatory effect.
Avoid in pregnancy, stimulates uterine contractions. Avoid with active peptic ulcers due to bitter stimulation of gastric secretion. May potentiate anticoagulants. Generally well tolerated otherwise.
Pregnancy: avoid
Breastfeeding: avoid
Active compounds: harpagoside
Remedies using Devil's Claw · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.